Clarus Therapeutics Holdings, Inc. (CRXT)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
CRXT Chart
Clarus Therapeutics Holdings, Inc. (CRXT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Clarus Therapeutics Holdings, Inc. ever had a stock split?
Clarus Therapeutics Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | NASDAQ (NMS) Exchange | 18271L107 CUSIP |
| US Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Clarus Therapeutics Holdings, Inc., based in Illinois and founded in 2003, is a pharmaceutical company dedicated to the development and commercialization of oral testosterone replacement therapies throughout the United States. The company focuses on innovative solutions for managing health issues related to low testosterone levels in men, specifically hypogonadism. Clarus Therapeutics is committed to advancing its therapeutic offerings and improving patient outcomes in this area. In addition, the company has entered into strategic licensing agreements that aim to expand its capabilities in androgenic treatments and proprietary technologies.
Products and Services
- JATENZO:
JATENZO is the flagship product of Clarus Therapeutics, consisting of a soft gel oral formulation of testosterone undecanoate. This medication is designed for the treatment of hypogonadism in men, addressing symptoms associated with low testosterone levels. JATENZO offers an alternative to traditional testosterone therapies by providing an easy-to-administer oral option, enhancing adherence and convenience for patients.
- Licensing Agreement with HavaH Therapeutics:
This strategic partnership focuses on developing androgenic treatments that target inflammatory breast disease and certain types of breast cancer. The collaboration aims to leverage both companies' expertise to bring innovative solutions to specific oncology patient populations, thereby expanding the therapeutic portfolio of Clarus Therapeutics beyond its primary focus on testosterone.
- Licensing Agreement with The Royal Institution for the Advancement of Learning/McGill University:
This agreement allows Clarus Therapeutics to advance proprietary technology designed to address CoQ10 deficiencies. By harnessing the research and development capabilities of McGill University, the company seeks to improve health outcomes in patients suffering from conditions related to CoQ10 deficiencies, potentially offering new avenues for treatment and care.
